Sign Up to like & get
recommendations!
0
Published in 2022 at "Xenobiotica"
DOI: 10.1080/00498254.2022.2116368
Abstract: Abstract RO7119929 is being developed as an orally administered prodrug of the TLR7-specific agonist and active drug, RO7117418, for the treatment of patients with solid tumours. In this publication, we present a case study wherein…
read more here.
Keywords:
pharmacological active;
active dose;
prodrug;
active drug ... See more keywords